Icbio Clinical Research Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
- Paid Up Capital ₹ 1.41 Cr
- Company Age 16 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.34 Cr
- Satisfied Charges ₹ 1.05 Cr
- Revenue Growth 22.11%
- Profit Growth -28.53%
- Ebitda -0.32%
- Net Worth 20.09%
- Total Assets 10.15%
About Icbio Clinical Research
Icbio Clinical Research Private Limited (ICRPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 07 October 2008 and has a history of 16 years and four months. Its registered office is in Bangalore North, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 1.41 Cr.
The company currently has active open charges totaling ₹5.34 Cr. The company has closed loans amounting to ₹1.05 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pushpa Latha and Harisha Seethanaik serve as directors at the Company.
Company Details
- Location
Bangalore North, Karnataka, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media
Corporate Identity Details
- CIN/LLPIN
U73100KA2008PTC047964
- Company No.
047964
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Oct 2008
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
What products or services does Icbio Clinical Research Private Limited offer?
Icbio Clinical Research Private Limited offers a wide range of products and services, including Computer & Mobile Apps Development, Application Development Service, Company Law & Labour Law Consultants, Statutory Compliance Services, Data Entry & Data Processing Service, Data Management.
Who are the key members and board of directors at Icbio Clinical Research?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Harisha Seethanaik ![]() | Managing Director | 07-Oct-2008 | Current |
Board Members (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Pushpa Latha ![]() | Director | 07-Oct-2008 | Current |
Financial Performance of Icbio Clinical Research.
Icbio Clinical Research Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 22.11% increase. The company also saw a substantial fall in profitability, with a 28.53% decrease in profit. The company's net worth Soared by an impressive increase of 20.09%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Icbio Clinical Research?
In 2023, Icbio Clinical Research had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹5.34 Cr
₹1.05 Cr
Charges Breakdown by Lending Institutions
- Karnataka State Financial Corporation : 3.60 Cr
- State Bank Of India : 1.74 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
17 Jul 2023 | Karnataka State Financial Corporation | ₹3.60 Cr | Open |
17 Dec 2018 | State Bank Of India | ₹1.74 Cr | Open |
23 Dec 2015 | State Bank Of Travancore | ₹7.50 M | Satisfied |
29 Mar 2014 | State Bank Of Travancore | ₹3.00 M | Satisfied |
How Many Employees Work at Icbio Clinical Research?
Icbio Clinical Research has a workforce of 30 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Icbio Clinical Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Icbio Clinical Research's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.